Search results
Showing 136 to 150 of 1371 results for patients and public
In development [GID-TA11184] Expected publication date: TBC
Avapritinib for treating advanced systemic mastocytosis ID3770
In development [GID-TA11382] Expected publication date: TBC
This guideline covers managing hip fracture in adults. It aims to improve care from the time people aged 18 and over are admitted to hospital through to when they return to the community. Recommendations emphasise the importance of early surgery and coordinating care through a multidisciplinary Hip Fracture Programme to help people recover faster and regain their mobility.
In development [GID-TA10999] Expected publication date: 21 August 2024
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
In development [GID-TA11106] Expected publication date: TBC
Find out more about quality standards advisory committee 3 members at NICE.
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: 29 January 2025
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
This guideline covers rehabilitation strategies for adults who have experienced a critical illness and stayed in critical care. It aims to improve physical, psychological and cognitive outcomes in people who have been discharged from critical care.
In development [GID-TA11039] Expected publication date: 21 August 2024
expenditure. You'll find this in the finance and workforce report section in our public board papers . Annual report . This includes our...
In development [GID-TA11355] Expected publication date: 09 July 2024
In development [GID-TA11288] Expected publication date: TBC
In development [GID-TA11186] Expected publication date: TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development [GID-TA10994] Expected publication date: TBC